Abstract: In some aspects of the present invention is a formulation comprising a solid dispersion or intimate mixture of a poorly water soluble drug and an ionic polymer surprisingly exhibiting fast disintegration of tablet.

Abstract: Tetrapeptides consisting of (I or V)-X1-K-X2, where X1 can be selected from E, Q or K, and X2 can be selected from M, F, I, W, or V, exhibit diverse bioactivities. They are multi-functional effector molecules to stimulate keratinocytes migration; neutralize the proinflammatory effect of bacterial cell wall components such as lipoteichoic acids of the Gram-positive S. aureus; and induce angiogenesis in cultured human umbilical vein endothelial cells. The downregulation of pro-inflammatory condition was also demonstrated using SOR-300-FT psoriasis skin model for representative peptide. The bioactivity was also supported by gene profiling study upon treatment of normal skin tissues using EPIDERM™ skin substitutes.

Abstract: Provided is a method for regulation of lipid metabolism comprising a step of administering to a subject in need thereof a therapeutically amount of pharmaceuticals. The pharmaceuticals comprise an effective amount of a composition containing a ferrous amino acid chelate and pharmaceutically acceptable carriers to regulate lipid metabolism. The amino acid is capable of being chelated with the ferrous iron in a chelated state stably as passing through a stomach. The composition containing the ferrous amino acid chelate can effectively control the variances of body weight and enhance metabolism of body fat of a subject. The pharmaceuticals prepared by the composition containing the ferrous amino acid chelate have effects on regulation of lipid metabolism.

Abstract: The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.

Abstract: Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Abstract: Provided are peptides that can inhibit collagen synthesis, processing and/or secretion. In some aspects, the therapeutic peptides may be used to treat a cancer such as, e.g., a pancreatic cancer or a glioblastoma.

Abstract: Polythioaminal polymers are made from hexahydrotriazine precursors and dithiol precursors. The precursors are blended together and subjected to mild heating to make the polymers. The polymers have the general structure wherein each R1 is independently an organic or hetero-organic group, each R2 is independently a substituent having molecular weight no more than about 120 Daltons, X and Z are each a sulfur-bonded species, at least one of X and Z is not hydrogen, and n is an integer greater than or equal to 1. X and Z may be hydrogen or a functional group, such as a thiol-reactive group. The reactive thiol groups of the polythioaminal may be used to attach thiol-reactive end capping species. By using water soluble or water degradable dithiols, such as polyether dithiols, water soluble polythioaminals may be made. Some such polymers may be used to deliver therapeutics with non-toxic aqueous degradation products.

Abstract: Examples may include a microsphere. The microsphere may include a biodegradable polymer. Furthermore, the microsphere may include a protein mixture selected from the group consisting of a protein-polyethylene glycol conjugate, the protein-polyethylene glycol conjugate and the hydrophobic anion of the organic acid, a protein and the hydrophobic anion of the organic acid, and combinations thereof. Examples may also include a method of making the microspheres. The method may further include reacting a polyethylene glycol with a protein to form a protein-PEG conjugate. In addition, the method may include protonating an amino group on the protein-PEG conjugate with a hydrophobic organic acid to form the protein-PEG conjugate salt. Furthermore, the method may include mixing the protein-PEG conjugate salt in an organic solvent with a biodegradable polymer. The method may also include emulsifying the mixture.

Abstract: Delivery systems and their methods of formation are generally provided. The delivery system can protect a delivery molecule (e.g., DNA/RNA) and deliver it into a cell via serum. In one embodiment, the method can include binding a delivery molecule with polyethylenimine such that an end of the delivery molecule is exposed; capping the end of the delivery molecule with a first biocompatible polymer to form a core; and encapsulating the core with a second biocompatible polymer. The resulting delivery system can include a delivery molecule bonded with polyethylenimine such that an end of the delivery molecule is exposed; a first biocompatible polymer electrostatically bonded to the end of the delivery molecule to form a core; and a second biocompatible polymer encapsulating the core.

Abstract: The present invention relates to a composition containing a chemokine, particularly, an interferon-inducible T-cell alpha chemoattractant (ITACT) which can decrease the gene expression of a factor related to melanin pigment production in melanocytes, thereby exhibiting a skin whitening effect.

Abstract: A method for preparing a thin film polymer structure having a functional substance on an A surface and a B surface of the film, the polymer structure being obtained by: (a) adsorbing polyfunctional molecules to a region of an arbitrary shape in an interface between a substrate body and a liquid phase; (b) polymerizing and/or crosslinking the adsorbing polyfunctional molecules to form a polymer thin film; (c) bonding a functional substance to the A surface of the formed thin film and then forming a soluble support film on the A surface; (d) exfoliating the thin film and the soluble support film from the substrate body; and (e) bonding to the B surface of the thin film a functional substance identical to or different from the functional substance bonded to the A surface and then dissolving the soluble support film with a solvent.

Abstract: The present invention relates to cosmetic compositions comprising polypeptides obtained or obtainable from Salmonidae hatching fluid, methods of producing said compositions and their use in various cosmetic applications to the skin, particularly for improving the cosmetic appearance of skin of a mammalian animal.

Abstract: The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.

Abstract: Activated aluminum sesquichlorohydrate (AASCH) powders and method of making are disclosed. The method of making the active comprises (a) diluting the concentrated aluminum sesquichlorohydrate (ASCH) solution to from about 10% to about 25% by weight and (b) heating the diluted solution to obtain a Band III polymer concentration of at least about 20% and a Band IV polymer concentration of at least about 15%, and (c) drying the heated solution to powders and (d) optionally screen or light mill the powders to free flowing spherical particles.

Abstract: The novel active ingredient combinations which consist of the compounds of the formula (I) in combination with further active insecticidal ingredients (II) are very suitable for control of animal pests such as insects and/or unwanted acarids.

Abstract: A thin film polymer structure having a functional substance on the face (A surface) and reverse face (B surface) of the film, obtained by the steps of: (a) causing polyfunctional molecules to adsorb to an area of an arbitrary shape in an interface between a substrate body and a liquid phase; (b) polymerizing and/or crosslinking the adsorbing polyfunctional molecules to form a polymer thin film; (c) bonding a functional substance to the A surface of the formed thin film and then (d) forming a soluble support film thereon; exfoliating the thin film and the soluble support film from the substrate body; (e) bonding to the B surface of the thin film a functional substance identical to or different from the abovementioned functional substance and then dissolving the soluble support film with a solvent.

Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

Abstract: A functionalized nanomaterial, such as a nanoparticle, can include a polythioaminal functionalized surface. The polythioaminal linked to the surface of the nanomaterial can be bonded to a compound such as therapeutic and/or diagnostic materials. The thiol-based linkages can be used to bond the polythioaminal to both the nanomaterial and the therapeutic and/or diagnostic materials. Polythioaminals can be prepared via reactions of triazine and dithiols. Polythioaminals thus prepared can be further modified to provide linkages to the nanomaterial and other compounds such as medicinal compound, peptides, and dyes. Nanomaterials including such compounds linked thereto via the polythioaminal can be supplied for therapeutic and/or diagnostic purposes to biological target regions.

Abstract: The present invention relates to a compound of formula (I) (R1-Arg-Gly-Asp-Gly-Ala-Asn-Pro-Asn-Ala-Ala-Gly-R2), formula II (R5-Arg-Gly-Asp-Gly-Pro-Gln-Gly-Pro-Gln-R6), or formula III (R9-Trp-Arg-Phe-Gln-Trp-Gln-Phe-Glu-Gln-R10), and to compositions comprising a compound of formulas I, II or III, as well as the use of said compounds and/or said compositions in the cosmetic treatment of skin and/or hair, and to the use thereof for inducing the formation of collagen.